Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
TIR domain-containing adapter molecule 1 (TICAM1), also widely known as Toll/IL-1 receptor domain-containing adapter-inducing interferon-beta (TRIF), is a critical intracellular adapter protein in the innate immune system. It plays an indispensable role in mediating MyD88-independent signaling downstream of Toll-like receptor 3 (TLR3) and Toll-like receptor 4 (TLR4). Upon activation by pathogen-associated molecular patterns (PAMPs) such as viral double-stranded RNA or bacterial lipopolysaccharide, TICAM1 is recruited to these receptors, where it undergoes phosphorylation and oligomerization to form signaling complexes. This recruitment leads to the activation of downstream kinases like TBK1 and IKKε, which phosphorylate interferon regulatory factor 3 (IRF3), driving the transcription of type I interferons and antiviral cytokines. Additionally, TICAM1 interacts with TRAF6 and RIPK1 to activate NF-κB, promoting pro-inflammatory cytokine production and apoptosis. Dysregulation of TICAM1 signaling is implicated in various pathological conditions; loss-of-function mutations are associated with increased susceptibility to severe viral infections, such as herpes simplex encephalitis, while overactivation can trigger acute lung injury and chronic inflammatory diseases. Consequently, TICAM1 is a highly attractive therapeutic target. Pharmacological modulation of the TICAM1 pathway is being explored using TLR agonists (e.g., Poly(I:C) and monophosphoryl lipid A) as vaccine adjuvants or cancer immunotherapies, as well as peptide inhibitors (e.g., Pepinh-TRIF) and small molecules to suppress excessive inflammation in diseases like Alzheimer's and acute lung injury.
Inhibition of TLR-TRIF interaction, activation of TLR3/TLR4-mediated TRIF signaling, inhibition of downstream TBK1/IKKε kinases, or downregulation of TRIF expression and signaling
9 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on TIR domain-containing adapter molecule 1 (TRIF) (TICAM1).